MarketPulse

NRX-100

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

NRx Pharmaceuticals Appoints First Chief Commercial Officer Ahead of Ketamine FDA Approvals

NRx Pharmaceuticals names Glenn Tyson as inaugural Chief Commercial Officer, bolstering leadership ahead of anticipated FDA approvals for ketamine products.
NRXPNRXPWBreakthrough Therapy DesignationFast Track designation
GlobeNewswire Inc.GlobeNewswire Inc.··Nrx Pharmaceuticals, Inc.

NRx Pharmaceuticals to Unveil 2025 Results, Update on Breakthrough Psychiatric Drug Pipeline

NRx Pharmaceuticals to report 2025 results March 24, 2026, updating on FDA-designated ketamine and PTSD programs with significant clinical potential.
NRXPNRXPWfinancial resultsclinical-stage biopharmaceutical